Galapagos completes recruitment for Darwin 1 study with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA

MECHELEN, Belgium, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 1 Phase 2B study with GLPG0634 has been completed.

Selective JAK1 inhibitor GLPG0634 (filgotinib) has shown a best-in-class profile in two 4-week Phase 2A studies in RA patients.  GLPG0634 is currently in a global Phase 2B program (DARWIN) in 875 RA patients and in a Phase 2 study in 180 patients with Crohn's disease. 

DARWIN 1 plans to enroll 595 patients with moderate to severe rheumatoid arthritis who insufficiently respond to methotrexate but remain on their background therapy of methotrexate.  DARWIN 1 is a double-blind, placebo-controlled evaluation of three doses of GLPG0634, as once- and twice-daily administration.  Following the closure of recruitment, the last patient will now be randomized in the study before the end of the month.  Topline, blinded results from the first 12 weeks of treatment in DARWIN 1 are expected around the end of Q1 2015, with topline 24 weeks results expected three months later.

DARWIN 2 plans to enroll 280 patients with moderate to severe rheumatoid arthritis who insufficiently respond to methotrexate.  DARWIN 2 is a double-blind, placebo-controlled investigation of three once-daily dose levels of GLPG0634 as monotherapy treatment.  Completion of recruitment for DARWIN 2 is expected in the coming weeks.  Topline results from 12 week results are expected in Q2 2015, with complete 24 week data package expected in Q3 2015.  AbbVie will base its licensing decision on the complete 24 week DARWIN 1 and 2 data packages from GLPG0634.

Dr Piet Wigerinck, Chief Scientific Officer of Galapagos, commented: "We are pleased that recruitment for Darwin 1 has been completed and that Darwin 2 is on track to complete recruitment in the coming weeks.  We see a good spread of patients coming in across the major geographic areas and continue to see more than 90% of patients who complete the DARWIN 1 and 2 studies enroll in the DARWIN 3 long-term extension study.  We are encouraged by this roll-over rate, and we look forward to seeing all the results next year."

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic disease.  In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634 .  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease.  Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).  AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene.  Potentiator GLPG1837 is expected to start Phase 1 in 2014.  Galapagos also expects to nominate a pre-clinical candidate corrector before year end 2014.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1870603

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 144

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 121

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 90

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 96

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 28

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Trifork Group Launches 2025 Share-Based Incentive Program

Updated Category News Views 333

Trifork's Innovative Share-Based Incentive Program The Trifork Group AG has taken a significant step towards enhancing employee satisfaction and retention with the introduction of its Share-Based Incentive Program for 2025. This strategic decision supports Trifork’s ongoing commitment to fostering a motivated workforce and aligns with the company’s vision for growth...

Continue Reading
China's Agricultural Modernization: Dezhou's Vital Role

Updated Category News Views 40

Modern Farming Revolution in Dezhou Fifteen years ago, farming technology in Dezhou was a distant dream; today, it's a shining reality. Picture this: Song Zhijie, a veteran farmer, reflecting on a dusty 1997 summer harvest. Now, he sits in air-conditioned cabins, operating state-of-the-art machinery, basking in the efficiency that modern technology has granted. Dezhou, a...

Continue Reading
Exploring the Growth of the Cultured Wheat Market: 2024-2034

Updated Category News Views 142

Exploring the Growth of the Cultured Wheat Market The cultured wheat market is set for remarkable growth, with projections indicating an increase from USD 704.1 million in 2024 to USD 1,273.0 million by 2034. This growth translates to a solid compound annual growth rate (CAGR) of 6.1% over the decade. The rising demand for cultured wheat is driven by several factors,...

Continue Reading
Transforming Urban Mobility: Hikvision's AIoT Innovations

Updated Category News Views 292

Hikvision showcased its game-changing AIoT innovations at the ITS World Congress, zeroing in on making urban mobility safer, smarter, and greener. Their booth was abuzz with tech that’s not just flashy; it’s a serious play aimed at reshaping how we think about transport. The emphasis here? A commitment to road safety that's palpable, with cutting-edge solutions that...

Continue Reading
Avem Health Partners Welcomes Military Veterans to Board of Directors

Updated Category News Views 90

Enhancing Leadership at Avem Health Partners Avem Health Partners, a well-respected hospital management company based in Oklahoma City, is excited to announce the recent appointments of Keith Walker and Barbara Holcomb to its Board of Directors. This strategic decision aims to infuse the organization with a wealth of experience from both military and corporate...

Continue Reading